May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Primary Intravitreal Bevacizumab (Avastin) for the Treatment of Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Results of the Pan-American Collaborative Retina Study Group (PACORES) at 6-Months Follow-Up
J. J. Fromow-Guerra; F. J. Arevalo; H. Quiroz-Mercado; J. G. Sanchez; F. E. Michel; M. H. Berrocal; J. A. Roca; M. J. Saravia; L. Wu; Pan-American Collaborative Retina Study Group(PACORES)
Author Affiliations & Notes
  • J. J. Fromow-Guerra
    Retina, APEC, Mexico City, Mexico
  • F. J. Arevalo
    Retina, the Retina and Vitreous Service, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela
  • H. Quiroz-Mercado
    Retina, APEC, Mexico City, Mexico
  • J. G. Sanchez
    Retina, the Retina and Vitreous Service, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela
  • F. E. Michel
    Retina, Universidade Federal de São Paulo - Departamento de Oftalmologia - Instituto da Visão, Sao Paolo, Brazil
  • M. H. Berrocal
    Retina, University of Puerto Rico, San Juan, Puerto Rico
  • J. A. Roca
    Retina, Instituto especializado de oftalmología Lima, Lima, Peru
  • M. J. Saravia
    Retina, Hospital Universitario Austral, Buenos Aires, Argentina
  • L. Wu
    Retina, Instituto de Cirugia Ocular, San Jose, Costa Rica
  • Pan-American Collaborative Retina Study Group(PACORES)
    Retina, APEC, Mexico City, Mexico
  • Footnotes
    Commercial Relationships J.J. Fromow-Guerra, None; F.J. Arevalo, None; H. Quiroz-Mercado, None; J.G. Sanchez, None; F.E. Michel, None; M.H. Berrocal, None; J.A. Roca, None; M.J. Saravia, None; L. Wu, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4569. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Primary Intravitreal Bevacizumab (Avastin) for the Treatment of Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Results of the Pan-American Collaborative Retina Study Group (PACORES) at 6-Months Follow-Up
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      J. J. Fromow-Guerra, F. J. Arevalo, H. Quiroz-Mercado, J. G. Sanchez, F. E. Michel, M. H. Berrocal, J. A. Roca, M. J. Saravia, L. Wu, Pan-American Collaborative Retina Study Group(PACORES); Primary Intravitreal Bevacizumab (Avastin) for the Treatment of Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD): Results of the Pan-American Collaborative Retina Study Group (PACORES) at 6-Months Follow-Up. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4569.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose:: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)

Methods:: Interventional retrospective multicenter study in 8 centers from 7 countries in patients with CNV and AMD who were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab. Patients underwent ETDRS testing of BCVA, ophthalmoscopic examination, OCT, and fluorescein angiography (FA) at baseline and follow-up visits. Main outcome measures included changes in BCVA, OCT and FA. Repeated measures analysis of variance was used to compare mean values.

Results:: 92 eyes of 87 consecutive patients with a mean age of 75.6 ± 8.3 years were included. Mean follow-up 6.8 months (range 6 to 10 months). 46 (50%) eyes needed a second injection at a mean of 9.4 ± 6.2 weeks, fifteen (16.1%) eyes required a third injection at a mean of 9.2 ± 4.0 weeks , and ten (10.9%) eyes required four o more injections. The mean baseline BCVA was logMAR = 1.25 and the final mean BCVA was logMAR = 1.0, (p < 0.0001). Final BCVA showed 33 (35.9%) eyes remained stable, 46 (50%) eyes improved two or more lines, and 13 (14.1%) eyes decreased two or more lines. Mean central macular thickness at baseline by OCT was 345.18 µm ± 154.3 µm and decreased to 257.8 µm ± 94.1 at the end of follow-up (p < 0.0001). Adverse events included transient increased intraocular pressure in 2 (2.2%) eyes, transient hypotony in one (1.1%) eye and endophthalmitis in 2 (2.2%) eyes. No systemic adverse events were observed.

Conclusions:: Primary intravitreal bevacizumab at doses of 1.25 mg or 2.5 mg seem to provide stability or improvement in BCVA, OCT and FA in CNV secondary to AMD at 6-months.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: outcomes/complications • retina 
© 2007, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept